Current trends in antiviral drug development

De Clercq, Erik

We noted you are experiencing viewing problems

Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems.
No luck yet? More tips for troubleshooting viewing issues
Contact HST Support access@hstalks.com

Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
For additional help, please don't hesitate to contact HST support access@hstalks.com

We hope you have enjoyed this limited-length demo

Request free trial
Recommend to your librarian

Share
Share This Talk
Messaging

Outlook

Gmail

Yahoo!

WhatsApp
Social

Facebook

X

LinkedIn

VKontakte
Permalink
Replay Talk

This is a limited length demo talk; you may login or review methods of obtaining more access.

Slides
Topics
Links
Citation

Printable Handouts

PDF

Navigable Slide Index

Introduction
Introduction - ten commandments
IDU
TFT
Methisazone
Amantadine
Ribavirin
Ara-A
HIV
Replicative cycle of HIV
Suramin
Zidovudine
Emtricitabine
TDF
Drug interrelations and combination
Truvada
Atripla
Complera
Quad (stribild)
GS-7340
Quad (planned)
Another planned quad
Cobicistat & Ritonavir
HCV
HCV genome and potential targets
Available HCV drugs
Telaprevir
Boceprevir
Asunaprevir
GS-9256
GS-9451
Danoprevir
Vaniprevir
Narlaprevir
Simeprevir
Drugs which target NS5A
Daclatasvir
Drugs that target NS5B (nucleoside)
Sofosbuvir
Mericitabine
Drugs that target NS5B (non-nucleoside)
VX-222
BI 201335
Tegobuvir
Setrobuvir
Filibuvir
VCH-916 & VCH-759
Drugs that target cellular enzymes
Alisporivir
The principle for the future treatment of HCV
Phase II DAA-based combination clinical trials
HSV
Acyclovir
Valaciclovir
Penciclovir & Famciclovir
HSV DNA synthesis
AIC316
VZV
BVDU
Degradation of BVDU to BVU
Cf 1743 & FV-100
ASP2151
HCMV
Ganciclovir & Valganciclovir
Phosphonoformic acid: Foscarnet
HPMPC
Maribavir
Letermovir
Poxviruses
Post-exposure treatments for monkeypox virus
HDP-cidofovir
ST-246
HBV
Anti-HBV agents
Lamivudine
Adefovir dipivoxil
Entecavir
Telbivudine
Viread
CHB virologic response
Influenza virus
Antiviral influenza replication inhibition
Zanamivir
Oseltamivir (tamiflu)
Tamiflu packaging
RWJ-270201: Peramivir
Laninamivir octanoate
Favipiravir
Favipiravir mechanism
Enveloped viruses
Neplanocin A
dUY11
LJ-001
FGI-106
Picornaviruses
Pleconaril
Pirodavir
Rupintrivir
TBZE-029
City hall
Rega institute building
Henri Joseph Rega
Mentor
Seed of wisdom

Topics Covered

Chemotherapy of virus infections, AIDS, and malignant diseases
Molecular mechanism of action & enzyme targets of antiviral and antitumor agents
Nucleoside and nucleotide analogues
Reverse transcriptase inhibitors
Virus adsorption, fusion and uncoating inhibitors

Links

Series:

Categories:

Therapeutic Areas:

Infectious Diseases

Talk Citation

De Clercq, E. (2013, September 23). Current trends in antiviral drug development [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/LHVX4583.
Export Citation (RIS)